Use of Raman Spectroscopy to Decrease Time to Identify the Species of Candida and bacterial Growth in Cultures.

Case ID:
15-1270

Use of Raman Spectroscopy to Decrease Time to Identify MRSA Verses MSSA and the Subspecies of Candida and bacterial Growth in Cultures  

WSU Tech#: 15-1270

Technology Summary:

New Technology for the identification of MRSA versus MSSA and sub-species for both bacterial staph Aureus (SA) and Candida in one package, using Raman Spectroscopy.

 

This work has been underway at Wayne State University and an algorithm for the detection has been generated to determine a cultures antibiotic resistance (MRSA and MSSA) and sub-species identification in bacteria and Candida. 

 

Competitive Advantages

 

No competitors found for this software on Raman Spectroscopy equipment.

 

Benefit Analysis:

 

For Candida, there are 17 different species; however, more than 90 % of invasive infections are caused by Candida albicans, Candida glabrata, Candida parapsilosis, Candida tropicalis and Candida krusei.  The therapy for each of these species differs and the wrong treatment may destroy commensurable Candida, allowing the pathogenic Candida to flourish; so it is important to identify the proper sub-species and align the proper treatment.  There are roughly between 25,300 to 31,600 cases of Candida infection per year, making this a fairly sizeable market.  Of critical importance is the 2,965 to 11,858 neonates that contract Candida each year.  These patients likely have one opportunity to receive proper treatment or the infection may be fatal.

For bacterial infections, Methicillin-susceptible staphylococcus aureus (MSSA) market is growing at faster pace majorly due to increasing rate of morbidity and mortality of the MSSA infection. Additionally, the extensive research and development activities with respect to the development of the more efficient and less time consuming drugs is also driving the market of methicillin-susceptible staphylococcus aureus.  Recognizing that a SA is multidrug resistant (MDR) and the sub-species of that SA, can ensure proper measures are taken in treating the patient, other patients in the facility (preventing nosocomial infections) and protecting healthcare workers.  According to the SENTRY Antimicrobial Surveillance Program, which examined >81,000 isolates during the period 1997–2002, S. aureus was the most common cause of nosocomial bacteremia in North America (prevalence, 26.0%) and was the second most common cause of nosocomial bacteremia in Europe (prevalence, 19.5%)

Stage of Development: Preclinical

 

This is a new algorithm for current spectrophotometers.  More information on this patent pending technology if there is available.

 

Patent Status:

 

Through the Office of Technology Commercialization at Wayne State University, we have filed a patent application to the USPTO office. This is a detailed methods patent application.

 

Licensing Opportunity:

WSU is looking for a commercial partners interested in furthering the validation of this technology and bringing the technology to market.  The inventors would be open to assist in the generation of SBIR/STTR  grants to fund the further development of this technology.

 

Contact for Further Information:  

Frank Urban, MS, CBA, BA.   email: frank.urban@wayne.edu   Phone (mobile): (734) 355-0730

Patent Information:
For Information, Contact:
Frank Urban
Commercialization Principal
Wayne State University
frank.urban@wayne.edu
Inventors:
Nitin Chouthai
Keywords: